Other languages Biofrontera Inc.

Equities

BFRI

US09077D2099

Market Closed - Nasdaq Other stock markets 02:00:01 30/04/2024 am IST			5-day change	1st Jan Change
1.73 ^USD	+8.81%		+19.73%	-37.54%

18/03	Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024
15/03	Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	16/03
Biofrontera Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/03
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	11/03
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera Ag	20/02
MORNING BRIEFING - Deutschland/Europa -2-	16/02
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use	06/02
Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	12/01
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023	10/11
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	10/23/10
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)	10/23/10
Biofrontera Inc. Provides Revenue Guidance for the Third Quarter and Nine Months of 2023 and Re-Affirms Revenue Guidance for the Year 2023	04/23/04
Biofrontera Inc. Appoints Samantha Widdicombe as Senior Director, Strategic Accounts and Communications	29/23/29
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	28/23/28
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)	28/23/28
Biofrontera Inc. Affirms Guidance for 2023	11/23/11
Biofrontera Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	10/23/10
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-Pdt for the Treatment of Basal Cell Carcinoma	10/23/10
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note	21/23/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biofrontera Inc.

Equities

BFRI

US09077D2099

Other languages

Filters